Egetis Therapeutics AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	55.4	46.1	57.6	22.6	38.2	40.66
Revenue	55.4	46.1	57.6	22.6	38.2	40.66
Revenue Growth (YoY)	-18.41%	-19.96%	154.87%	-40.84%	-6.05%	-50.75%
Cost of Revenue	38.6	11.6	11	142.6	96.6	185.17
Gross Profit	16.8	34.5	46.6	-120	-58.4	-144.51
Selling, General & Admin	201.5	215.3	172.8	74.3	44.6	32.15
Research & Development	140.6	146.2	194	-	-	-
Other Operating Expenses	-8.8	-5.2	-8.9	-	-0.3	-
Operating Expenses	333.3	356.3	357.9	77	46.8	32.55
Operating Income	-316.5	-321.8	-311.3	-197	-105.2	-177.06
Interest Expense	-15.4	-17.6	-4.2	-0.1	-0.2	-0
Interest & Investment Income	6.9	6.9	4.9	0.9	0.1	0.16
Currency Exchange Gain (Loss)	-6.3	-6.3	-13.4	2.4	0.6	-1.13
Other Non Operating Income (Expenses)	-1.7	-4.5	-2.8	-	0.2	0
Pretax Income	-333	-343.3	-326.8	-193.8	-104.5	-178.02
Income Tax Expense	0.3	0.3	0.1	-	-	-
Net Income	-333.3	-343.6	-326.9	-193.8	-104.5	-178.02
Net Income to Common	-333.3	-343.6	-326.9	-193.8	-104.5	-178.02
Shares Outstanding (Basic)	357	307	257	194	180	67
Shares Outstanding (Diluted)	357	311	260	194	180	67
Shares Change (YoY)	22.32%	19.57%	33.86%	7.97%	166.96%	30.54%
EPS (Basic)	-0.93	-1.12	-1.27	-1.00	-0.58	-2.64
EPS (Diluted)	-0.93	-1.12	-1.30	-1.00	-0.60	-2.64
Free Cash Flow	-229.3	-227.9	-278.4	-173.5	-130.3	-134.66
Free Cash Flow Per Share	-0.64	-0.73	-1.07	-0.89	-0.72	-2.00
Gross Margin	30.33%	74.84%	80.90%	-	-152.88%	-
Operating Margin	-571.30%	-698.05%	-540.45%	-871.68%	-275.39%	-435.43%
Profit Margin	-601.63%	-745.34%	-567.53%	-857.52%	-273.56%	-437.81%
Free Cash Flow Margin	-413.90%	-494.36%	-483.33%	-767.70%	-341.10%	-331.18%
EBITDA	-291.03	-319.1	-310.2	-195.8	-104	-176.88
EBITDA Margin	-	-	-	-	-272.25%	-
D&A For EBITDA	25.48	2.7	1.1	1.2	1.2	0.18
EBIT	-316.5	-321.8	-311.3	-197	-105.2	-177.06
EBIT Margin	-	-	-	-	-275.39%	-
Revenue as Reported	-	-	-	22.6	38.5	40.66

Source: S&P Global Market Intelligence. Standard template. Financial Sources.